To provide a new compound useful as an active component of pharmaceuticals.
The phosphonic acid diester derivative is expressed by general formula (1) (R1 is NR7R8; one of R7 and R8 is H and the other is a lower alkyl having a substituent selected from pyridyl, morpholino, hydroxy, furyl, lower alkoxy, imidazolyl, lower alkylthio, N-(phenyl-lower alkyl)piperidinyl and N- lower alkyl-substituted pyrrolidinyl, an N,N-di-lower alkylamino, piperidinyl, benzylideneimino having a halogen atom or a lower alkoxy on the phenyl ring, or a 7-12C alkyl or R7 and R8 together with the bonding nitrogen atom form an N-lower alkyl-substituted piperazinyl or morpholino; R2 groups are each a lower alkyl; and R3, R4, R5 and R6 are each independently H or a halogen atom). The invention further provides an ACAT-1 inhibitor containing the derivative as an active component.
| JP2011501731 | Mitochondrial targeted antitumor agent |
| WO/2020/123827 | THRΒ RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF |
| JP2014040462 | ORAL FORMULATION COMPOSITION |
MIYATA KAZUYOSHI
SAKAI YASUHIRO
KURODA AKINARI
INOUE YASUHIDE
HAGI AKIFUMI
MIKI SHINYA
YOSHINAGA YOSHIHIRO
DOI MASAKO
TSUDA YOSHIHIKO
